SUNNYVALE, Calif.–(BUSINESS WIRE)–PQ Bypass, Inc., today announced it has received conditional approval of its investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate the pivotal DETOUR II clinical trial. As the first-ever pivotal trial for […]
Tag: PQ Bypass
PQ Bypass Reports Positive Results For The Novel DETOUR System In Patients With Tough To Treat Long Blockages In The Femoropopliteal Artery
SUNNYVALE, Calif.–(BUSINESS WIRE)–A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ DETOUR System for treating long-segment (>25 cm) blockages in the femoropopliteal artery. The data were presented as a late breaking […]
PQ Bypass to Unveil New Data From DETOUR I at VIVA 17
SUNNYVALE, Calif.–(BUSINESS WIRE)–PQ Bypass today announced that data from a subset analysis of the DETOUR I clinical trial will be presented during a late-breaking clinical trial session at Vascular InterVentional Advances (VIVA 17), taking place September 11-14 in Las Vegas. […]
PQ Bypass Earns Frost & Sullivan’s European Technology Innovation Award for Its Proprietary DETOUR System for Percutaneous Bypass
LONDON, Aug. 31, 2017 /PRNewswire/ — Frost & Sullivan is pleased to recognize PQ Bypass with the 2017 European PAD Interventions Technology Innovation Award. PQ Bypass’ DETOUR System is a minimally invasive technology that enables physicians to re-direct, or detour, blood flow around […]